GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Hyperfine Inc (NAS:HYPR) » Definitions » Intrinsic Value: Projected FCF

Hyperfine (Hyperfine) Intrinsic Value: Projected FCF : $0.00 (As of May. 15, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Hyperfine Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-05-15), Hyperfine's Intrinsic Value: Projected FCF is $0.00. The stock price of Hyperfine is $0.90. Therefore, Hyperfine's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Hyperfine's Intrinsic Value: Projected FCF or its related term are showing as below:

HYPR's Price-to-Projected-FCF is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.78
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Hyperfine Intrinsic Value: Projected FCF Historical Data

The historical data trend for Hyperfine's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyperfine Intrinsic Value: Projected FCF Chart

Hyperfine Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Intrinsic Value: Projected FCF
- - - - -

Hyperfine Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Hyperfine's Intrinsic Value: Projected FCF

For the Medical Devices subindustry, Hyperfine's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hyperfine's Price-to-Projected-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Hyperfine's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Hyperfine's Price-to-Projected-FCF falls into.



Hyperfine Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



Hyperfine  (NAS:HYPR) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Hyperfine's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=0.90/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hyperfine Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Hyperfine's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Hyperfine (Hyperfine) Business Description

Traded in Other Exchanges
N/A
Address
351 New Whitfield Street, Guilford, CT, USA, 06437
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. Legacy Hyperfine and Liminal represent two operating segments of the company. The company derives its sales from the following sources: 1) device sales which consist of sales of MRI devices and 2) service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.
Executives
Thomas Teisseyre officer: Chief Operating Officer C/O HYPERFINE, INC., 351 NEW WHITFIELD STREET, GUILFORD CT 06437
Khan Siddiqui officer: See Remarks 530 OLD WHITFIELD STREET, GUILFORD CT 06437
Brett Hale officer: Chief Administrative Officer C/O HYPERFINE, INC., 351 NEW WHITFIELD STREET, GUILFORD CT 06437
Maria Sainz director C/O ORTHOFIX INTERNATIONAL N. V., 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Jonathan M Rothberg director, 10 percent owner C/O BUTTERFLY NETWORK, INC., 530 OLD WHITFIELD ST., GUILFORD CT 06437
Alok Gupta officer: Chief Financial Officer 530 OLD WHITFIELD STREET, GUILFORD CT 06437
Neela Paykel officer: Gen Counsel & Corp Secretary 530 OLD WHITFIELD STREET, GUILFORD CT 06437
David D Scott director, officer: President and CEO 530 OLD WHITFIELD STREET, GUILFORD CT 06437
Ruth A Fattori director 1303 EAST ALGONQUIN ROAD, SCHAUMBURG IL 60196
Hc Sponsor Llc 10 percent owner 31 HUDSON YARDS, 10TH FLOOR, 28TH FLOOR, NEW YORK NY 10001
Arthur Bruce Cohen 10 percent owner 12 SOUTH MAIN STREET, SUITE #203, NORWALK CT 06854
Healthcor Group, Llc 10 percent owner 31 HUDSON YARDS, 10TH FLOOR, NEW YORK NY 10001
Joseph Patrick Healey 10 percent owner 31 HUDSON YARDS, 10TH FLOOR, NEW YORK NY 10001
R Scott Huennekens director C/O VOLCANO CORPORATION, 11455 EL CAMINO REAL, SUITE 460, SAN DIEGO CA 92130
Scott A. White officer: Chief Commercial Officer 530 OLD WHITFIELD STREET, GUILFORD CT 06437